By Cristina Gallardo
The U.S.'s drug regulator has approved Roche's Susvimo drug for the treatment of diabetic macular edema, the leading cause of diabetes-related blindness, the pharmaceutical company said.
Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained improvements in the vision of people with diabetic macular edema.
Susvimo is a refillable eye implant surgically inserted into the eye of a patient. The implant delivers a customized formulation of ranibizumab over time.
Diabetic macular edema affects more than 29 million adults worldwide.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
02-04-25 1216ET